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2Abstract
Glucocorticoids (GCs) play a key role in skin homeostasis and stress responses acting through 
the GC receptor (GR), which modulates gene expression by DNA binding-dependent 
(transactivation) and -independent (transrepression) mechanisms. To delineate which 
mechanisms underlie the beneficial and adverse effects mediated by GR in epidermis and other 
epithelia, we have generated transgenic mice that express a mutant GR (P493R, A494S), which 
is defective for transactivation but retains transrepression activity, under control of the keratin 5
promoter (K5-GR-TR mice). K5-GR-TR embryos exhibited eyelid opening at birth and corneal 
defects that resulted in corneal opacity in the adulthood. Transgenic embryos developed normal 
skin although epidermal atrophy and focal alopecia was detected in adult mice. 
GR-mediated transrepression was sufficient to inhibit keratinocyte proliferation induced 
by acute and chronic PMA exposure, as demonstrated by morphometric analyses, BrdU 
incorporation and repression of K6, a marker of hyperproliferative epidermis. These anti-
proliferative effects were mediated through negative interference of GR with MAPK/AP-1 and 
NF-κB activities, although these interactions occurred with different kinetics. However, PMA-
induced inflammation was only partially inhibited by GR-TR, which efficiently repressed IL-
1β and MMP-3 genes while weakly repressing IL-6 and TNF-α. Our data highlight the 
relevance of deciphering the mechanisms underlying GR actions on epithelial morphogenesis as 
well as for its therapeutic use in order to identify more restricted targets of GC administration. 
3Introduction 
Glucocorticoid (GC) hormones, acting 
through the GC receptor (GR), mediate 
profound and diverse physiological effects 
in vertebrate development, metabolism, 
neurobiology, and programmed cell death 
(1). GR is a ligand-activated transcription 
factor, which can modulate gene expression 
through mechanisms that are DNA-binding-
dependent (transactivation) and -
independent (transrepression). These two 
mechanisms can be genetically separated 
and it was demonstrated that, contrary to 
GR-/- mice that die perinatally, mouse 
mutants with a point mutation in the DNA 
binding domain of GR (GRdim/dim), unable to 
homodimerize and thus transactivate, were 
viable (2, 3). These mouse models revealed 
that the DNA-binding dependent actions of 
GR are not essential for survival and 
allowed to assign specific roles to the 
transactivation and transrepression 
functions of GR in different 
physiopathological systems (4). 
GR signaling is key in early life 
since prenatal GCs alter the rate of 
maturation of organs such as the lung, 
heart, kidney, gut and epidermis (5); 
accordingly, GR-/- mice died due to a 
respiratory failure. These early GC effects 
are routinely exploited in the clinic by 
antenatal administration of corticosteroid to 
premature infants in order to accelerate 
lung epithelium differentiation as well as 
skin barrier formation (reviewed in 6). 
Despite these beneficial effects, it is well 
known that maternal exposure to GCs 
causes birth defects by mechanisms which 
are still not well understood (5). We have 
previously reported that overexpression of 
wt GR in keratinocytes of the epidermis, 
hair follicles (HF) and other stratified 
epithelia by means of the keratin k5
promoter (K5-GR mice) elicited major 
phenotypic alterations including epidermal 
hypoplasia, dysplastic HFs, incomplete 
closure of the eyelids and maldevelopment 
of tooth, palate and secretory glands (7-9). 
Altogether, it seems that a precise 
spatiotemporal expression pattern of GR 
and its ligand is required to modulate many 
morphogenetic processes, particularly 
epithelial morphogenesis. 
On the other hand, GC analogs 
have been prescribed for more than fifty 
years as a treatment for numerous disorders 
involving hyperproliferation and 
inflammation due to their therapeutic 
efficacy. However, the adverse side-effects 
associated to the long-term treatments 
and/or elevated doses of GCs limit their 
clinical applications (1, 4). It has been long 
assumed that the therapeutic potential of 
GC analogs is exerted mostly through the 
transrepression function of GR whereas 
adverse side-effects are predominantly 
mediated by transactivation function of GR 
(1, 10).
In an attempt to delineate the 
mechanisms responsible for the beneficial 
versus adverse effects of GR in epidermis 
and other epithelia, we have generated a 
novel transgenic mouse model by 
expressing a mutant GR (P493R, A494S), 
which is unable to dimerize and 
transactivate but retains transrepression 
activity, under control of the k5 promoter 
(K5-GR-TR mice). Our data show that the 
transrepression function of GR was 
sufficient to cause eyelid opening at birth 
and corneal defects that resulted in corneal 
opacity in the adulthood. K5-GR-TR 
embryos developed normal skin but adult 
mice exhibited epidermal atrophy, patchy 
alopecia and underdeveloped vibrissae. 
In adult transgenic mice, GR-TR 
was sufficient to inhibit keratinocyte 
proliferation induced by acute and chronic 
PMA exposure, as shown by morphometric 
analyses, BrdU in vivo incorporation and 
drastic inhibition of the marker of 
hyperproliferative epidermis K6. GR-TR 
inhibited keratinocyte growth by interfering 
with MAPK/AP-1 and NF-κB activities. In 
contrast, PMA-induced inflammation was 
not efficiently inhibited by GR-TR, which 
down-regulated IL-1β and MMP-3 although 
repressed IL-6 and TNF-α only weakly. 
This transgenic mouse model opens new 
perspectives in deciphering the mechanisms 
responsible for GR impact on epithelial 
morphogenesis and also may help to 
identify more restricted targets of GC 
administration in the treatment of cutaneous 
pathologies.
4Results
Generation of skin-targeted mice 
expressing the transrepression function of 
GR
We aimed to investigate the consequences 
of expressing a mutant GR in skin, which is 
defective in transactivation but effective in 
transrepression. To do this, we placed a 
mutant GR containing two adjacent 
aminoacid substitutions (P493R, A494S) in 
the second half of the second zinc finger 
(11) under control of the keratinocyte-
specific k5 regulatory sequences (Fig. 1A). 
To test the functionality of this construct in 
the keratinocyte cell line PB, we transiently 
transfected either K5-GR-TR, K5-GR 
(containing the wt form of GR under the k5 
promoter, 7) or an empty vector along with 
the reporter plasmids MMTV-CAT or 8 x-
κB-CAT and evaluated CAT activity. 
Contrary to K5-GR, K5-GR-TR was unable 
to transactivate the MMTV promoter upon 
dexamethasone (Dex) treatment, whereas 
both constructs efficiently transrepressed a 
κB-containing promoter (Fig. 1B, upper 
panels). These results were not due to the 
different levels of transfected proteins since 
equivalent amounts of the wt and mutant 
GR were detected by immunoblotting using 
an anti-GR antibody (Fig. 1B, lower panel). 
We then microinjected the K5-GR-TR 
construct and obtained three founder 
transgenic mice (298, 306 and 599), of 
which two independent lines (298 and 306) 
were established. Transgene expression was 
analyzed by RT-PCR, immunoblotting, and 
immunolocalization (Fig. 1C-E). RT-PCR 
analyses using specific primers 
distinguished the endogenous (mGR) and 
transgene (rGR) transcripts in dorsal skin of 
wt and K5-GR-TR adult littermates (Fig. 
1C, line 298). Transgene mRNA was 
exclusively present in K5-GR-TR mouse 
skin whereas similar amounts of 
endogenous GR mRNA were detected in 
both wt and transgenic mice. At the protein 
level, line 298 showed the highest relative 
transgene expression in tail skin from 
founder mice as well as in back skin from 
adult transgenic mice of the F1 generation, 
as shown by immunoblotting (Fig. 1D). We 
thus performed most of the experiments in 
line 298 although results were also 
confirmed in line 306. Immunolocalization 
of GR in dorsal skin paraffin sections from 
newborn wt and transgenic mice 
demonstrated that endogenous GR was 
localized in the cytoplasm of suprabasal 
epidermal cells (Fig. 1E), whereas positive 
GR staining was additionally observed in 
interfollicular basal epidermis and outer 
root sheath (ORS) of HFs in transgenic 
mice (Fig. 1E, arrows). Transgene GR-TR 
was predominantly localized in the nucleus 
of keratinocytes, as observed for K5-GR 
transgenic mice (7).  
GR regulates embryonic eyelid closure 
through its transrepression function 
K5-GR-TR transgenic mice were viable and 
macroscopically normal, except that 
approximately 5% of newborn 
heterozygous (HT) mice showed eyelid 
opening at birth (EOB). When homozygous 
(HM) mice were generated, a fully 
penetrant EOB phenotype was observed 
and late embryos and newborn mice could 
be readily identified by this phenotype (Fig. 
2 and data not shown). Histological analysis 
revealed that eyelid fusion had failed in 
transgenic mice whereas the developing 
eyelids of control embryos had already 
fused at this stage (Fig. 2 B). Fig. 2B shows 
immunostaining using K5 to demonstrate 
that transgene expression was targeted to 
cornea (a, d), conjunctiva (b, e) and eyelid 
epithelia (c, f). Remarkably, corneal 
epithelium was almost absent in the 
transgenics (Fig. 2B, compare a and d) and 
the leading edge of the eyelid epithelium 
had a more restricted expression of K5 (Fig. 
2B, compare c and f); however, K5 staining 
in the conjunctival epithelium was similar 
between controls and transgenics (Fig. 2B, 
b, e). In many cases, we observed 
microphtalmia and dysplastic retinal tissue, 
most likely owing to a secondary effect of 
eye exposure intrautero (12). K5-GR-TR 
late embryos also had additional ocular 
malformations with severe cornea defects 
and attachment of eyelid epithelium tissue 
to the posterior side of the cornea (Fig. 2B, 
arrow). 
Since alterations in the 
developmental process of eyelid closure 
have been ascribed to defective JNK/c-jun 
signaling in other mouse models (13-15), 
we examined these pathways in transgenic 
late embryos and newborn mice. Total and 
phosphorylated forms of JNK and c-Jun 
5were detected at the leading edge of the 
eyelid epithelium regardless of whether the 
eyelid was fused or open (Fig. 2C, arrows, 
and data not shown). Therefore, our data 
suggest that the transrepression function of 
GR is sufficient to regulate ocular epithelial 
development although the precise 
mechanisms are still not known (see 
discussion). 
In the adulthood, the observed 
ocular defects correlated with corneal 
opacity in 100% of HM mice and around 
30% of HT mice (Fig. 2D). The Meibomian 
secretory glands of the eyelids, which also 
express K5 and are thus, targeted for 
transgene expression, were not altered in 
transgenic adult mice (Fig. 2E, 
arrowheads).
Different impact of the GR-mediated 
transrepression in embryonic and adult skin
We analyzed the skin histopathology of late 
embryos and newborn HT and HM K5-GR-
TR mice and found no significant changes 
in its architecture. Immunostaining showed 
no differences in the expression pattern of 
proliferation (K5) or differentiation markers 
(K10, filaggrin, loricrin, involucrin) of the 
developing epidermis or HFs (Fig. 3A and 
data not shown). BrdU incorporation of 
interfollicular keratinocytes in transgenic 
late embryos was unchanged as compared 
to wt mice (14.5% and 16.2%, 
respectively). However, adult HM 
transgenic mice developed patchy alopecia 
along the whole coat and throughout the 
face, with scarce and underdeveloped 
vibrissae (Fig. 3B). Immunostaining using 
an anti-keratin K5 antibody showed 
flattened keratinocytes with discontinous 
K5 staining in the adult HM epidermis (Fig. 
3C) and the number of HFs per mm was 
reduced approximately by 25% as 
compared to wt littermates (Fig. 4H). From 
these results, we conclude that 
overexpression of GR-TR in basal 
keratinocytes does not impair skin 
development during the embryogenesis but 
produces epidermal atrophy and reduced 
HF number in adult mice. 
GR transrepression is sufficient to inhibit 
keratinocyte proliferation in vivo 
We next investigated the hyperproliferative 
and inflammatory responses of adult K5-
GR-TR mice to acute and chronic PMA 
treatment (Fig. 4). The basal proliferation 
rate of interfollicular epidermal 
keratinocytes was equivalent in transgenic 
and control mice, as quantitated in paraffin 
sections incubated with an anti-BrdU 
antibody (Fig. 4A, B; 4%). After a single 
dose of PMA for 48h, the number of 
suprabasal layers augmented in control 
skin, correlating with an increase of up to 
45% in the labeling index of basal cells. 
However, PMA-induced proliferation was 
notably reduced (30%) in two independent 
K5-GR-TR transgenic lines (Fig. 4A, B), 
thus demonstrating that the transrepression 
function of GR is sufficient to inhibit 
induced keratinocyte growth. Moreover, 
when K5-GR mice were subjected to this 
PMA-treatment, we observed a similar 
response, indicating that the inhibitory 
effects of the wt form of GR and mutant 
GR-TR on keratinocyte proliferation were 
comparable (Fig. 4B). We also analyzed 
whether GR-TR effectively inhibited 
epidermal hyperplasia elicited by a chronic 
PMA treatment in HT and HM mice from 
lines 298 and 306 (Fig. 4 C, E). In addition, 
we studied the response of K5-GR mice to 
PMA in analogous experiments. Mice were 
treated with 2 μg of PMA every other day 
for 1-to 3-weeks and morphometric 
analyses were performed at various time-
points (Fig. 4C, E-H and data not shown). 
PMA caused maximum epidermal 
hyperplasia and increased number of HFs 
after 1-wk (Fig. 4C, E, H and data not 
shown). We also analyzed the expression of 
K6 as a marker of hyperproliferative skin 
and found positive staining throughout all 
epidermal layers of wt mice treated with 
PMA. In sharp contrast, K6 expression was 
drastically reduced in HT mice and K5-GR 
mice and was almost undetectable in the 
skin of HM animals (Fig. 4C, lower panel). 
We also found that the mRNA levels of 
k6β, the isoform of k6 being induced by 
PMA, among other hyperproliferative 
stimuli, were strongly reduced in PMA-
treated skin of K5-GR-TR and K5-GR mice 
(Fig. 4D). 
At 1-wk, epidermal width increased 
up to 53.1 ± 11.7 μm in wt mice as 
compared to 36.2 ± 7.9 μm in HT mice and 
20.7 ± 4.0 μm in HM animals. The 
reduction of epidermal width was also 
6statistically significant in transgenic line 
306 and in K5-GR mice (Fig. 4E). 
Consistent with this, BrdU incorporation 
was reduced by 50% in K5-GR-TR HT skin 
of line 298 and line 306 and by 80% in K5-
GR-TR HM line 298 and K5-GR skin (Fig. 
4F). We also investigated whether the 
presence of a GR-ligand could modulate the 
effect of the transgenes by treating the mice 
with PMA plus Dex for 1-wk. In all 
genotypes and transgenic lines, Dex 
significantly inhibited both epidermal 
hyperplasia and keratinocyte proliferation 
to a similar extent (Fig. 4E, F). 
We also evaluated the effect of GR-
TR in the PMA-induced anagenic growth of 
HFs. After 1-wk of PMA treatment, 
approximately 40% of HFs had entered into 
anagen, as quantitated by morphometrical 
analysis, in agreement with previous reports 
(16). However, only 20% of HFs in K5-
GR-TR HM mice and K5-GR mice was in 
the growing phase. Overall, these results 
support the notion that GR-TR exerts a 
potent anti-proliferative effect in 
keratinocytes of the epidermis and HFs. In 
contrast, dermal cellularity induced by 
PMA was reduced by only 15-20% in K5-
GR-TR mice, as compared to wt littermates, 
whereas this reduction reached 
approximately 30% in skin of K5-GR 
animals (Fig. 4G). The addition of Dex 
inhibited the effects of both transgenes on 
dermal cellularity to a similar extent. 
GR-mediated transrepression discriminates 
amongst pro-inflammatory cytokines in skin
We next asked whether GR and GR-TR 
differentially regulated the transcript levels 
of specific genes that are markers of 
proliferation and inflammation after PMA 
treatment, as compared to wt skin (Fig. 5). 
Given that effects on transcription may 
occur earlier than the time points used in 
our previous experiments (Fig. 4), we 
analyzed the effect of PMA 4-48h after the 
treatments by semiquantitative RT-PCR 
(Fig. 5). Additionally, as a control for 
ligand-induced activation of endogenous 
GR, groups of transgenic and wt mice were 
pretreated with Dex for 24h before PMA 
application (Fig. 5). In wt mice, the 
induction of the pro-inflammatory 
cytokines IL-6, TNF-α and IL-1β followed 
the expected kinetics, reaching a peak at 4h 
upon PMA treatment (Fig. 5). Pre-treatment 
with Dex diminished cytokine induction in 
wt skin, although to a different extent, with 
IL-1β being the cytokine most effectively 
repressed by addition of the ligand (Fig. 5). 
In K5-GR-TR transgenic mice, PMA-
induction of IL-6 and TNF-α transcripts 
was marginally reduced, although the 
differences relative to PMA-treated wt mice 
were not statistically significant, neither in 
the absence nor presence of Dex. However, 
mRNA levels of IL-6 and TNF-α were 
significantly reduced (1.7-fold) following 
4h of PMA exposure in K5-GR skin as 
compared to wt mice. Interestingly, the 
ability of PMA to induce IL-1β (4h and 
48h) was significantly inhibited by GR-TR 
and GR when compared to wt treated skin 
(Fig. 5, IL-1β). Transcriptional repression 
was equivalent for the K5-GR-TR line 298 
and K5-GR (5-fold) but less potent for K5-
GR-TR line 306 (3.5-fold). Dex further 
inhibited IL-1β gene induction by PMA at 
4h in both K5-GR-TR and K5-GR skin (4-
fold repression for K5-GR-TR line 298 and 
K5-GR and 2-fold repression for K5-GR-
TR line 306). 
We also examined the effects of 
PMA on the metalloprotease gene MMP-3, 
which is normally not expressed in 
untreated skin but is induced in dermal 
monocytic cells by PMA (17). The robust 
induction of MMP-3 which we observed in 
wt skin treated with PMA was significantly 
reduced in K5-GR-TR line 298 and K5-GR 
mice (1.6-fold). Pre-treatment with Dex 
further repressed transcription of MMP-3, 
ranging from 2- to 5-fold in the different 
genotypes (Fig. 5, MMP3). Finally, we 
evaluated cycD1 mRNA levels as a marker 
of PMA-induced proliferation (16) and 
although we observed a weak repression of 
this gene as a consequence of GR-TR and 
GR expression, these differences were not 
statistically significant. 
GR transrepression abrogates the PMA-
induced activation of JNK at early time 
points and reduces NF-κB binding at later 
stages 
MAPKs are crucial mediators of 
keratinocyte function (18) and GR 
negatively modulates these proteins in 
different physiopathological settings (19). 
7We thus examined whether the expression 
and/or activation of ERK and JNK played a 
role in the altered cutaneous responses of 
K5-GR-TR transgenic mice to PMA. Total 
protein and phosphorylated (P-) isoforms of 
ERK and JNK were checked by 
immunoblotting using whole cell extracts 
from adult K5-GR-TR and wt skin, 
quantitated, and expressed as relative 
MAPK activity (Fig. 6). In wt mice, PMA 
induced P-ERK activation at 2h, which 
remained high up to 8h. GR-TR decreased 
the basal rate of ERK phosphorylation 
although the kinetics of PMA induction 
were similar as that for wt mice (Fig. 6A, 
B). Notably, PMA caused a robust and 
transient JNK activation (10- to 12- fold) 
that was abrogated in K5-GR-TR skin. It is 
also important that GR-TR augmented 
constitutive basal c-Jun levels (Fig. 6A), 
which is in agreement with previous work 
reporting that Dex induces up-regulation of 
c-jun through DNA-binding independent 
mechanisms (17). Surprisingly, c-Fos was 
similarly increased by GR-TR expression. 
Remarkably, and contrary to PMA-induced 
accumulation of Jun and Fos proteins in wt
skin, we did not observe any increase in 
these AP-1 proteins in K5-GR-TR PMA-
treated skin (Fig. 6A). 
We also evaluated the implication 
of NF-κB activation in the GR-TR 
mediated effects on the cutaneous responses 
to acute and chronic PMA (Fig. 7). At early 
times, PMA induced NF-κB binding to a 
similar extent in both wt and transgenic 
skin. NF-κB complexes in adult skin 
consisted of p50/p65 and p50/p50 dimers, 
as determined by supershift assays (Fig. 
7A, right panel). After 1-wk of PMA 
exposure, NF-κB binding was reduced in 
transgenic skin as compared to wt, thus 
indicating that the interference of GR with 
the binding of NF-κB occurs at later stages 
(Fig. 7A, see discussion). The observed 
differences in NF-κB binding were not due 
to changes in the amount and/or subcellular 
localization of p65 or IκBα, as shown by 
immunoblotting using skin fractionated 
extracts from transgenic and wt littermates 
(Fig. 7B). Moreover, the expression of 
either wt GR or GR-TR in keratinocytes did 
not transcriptionally induce ikba (Fig. 7C), 
ruling out that up-regulation of IκBα is 
necessary for GR-mediated inhibition of 
NF-κB activity in keratinocytes. Overall, 
our data indicate that GR transrepression 
antagonizes the PMA-induced activation of 
both JNK and NF-κB, although these 
interactions occur with different kinetics. 
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Role of GR-TR in epithelial development 
We have generated a novel transgenic 
mouse model that expresses the 
transrepression function of GR in an 
attempt to better understand the 
mechanisms of GR action in the 
physiopathology of the epidermis, 
cutaneous appendages and other stratified 
epithelia. It is important to note that, similar 
to other published dimerization mutants, the 
P493R, A494S mutant used in our study is 
not globally deficient in transactivation as 
these mutants were competent for GRE 
binding or transcriptional enhancement of 
some genes, such as PNMT (20, 21). This 
implies that the mechanisms through which 
GR-TR can regulate keratinocyte responses 
include, not only transrepression, but also 
transactivation of genes with a more 
complex GRE configuration, as previously 
reported for other GC-target genes (20, 21). 
Our previous work demonstrated 
that overexpression of the wt form of GR 
(K5-GR mice) caused numerous congenital 
malformations of ectodermal-derived 
tissues, including the epidermis, HFs, eyes, 
teeth, and exocrine glands (7-9). One of the 
aims of this work was to decipher whether 
the transrepression function of GR was 
sufficient to produce abnormal epithelial 
development in these tissues. The fact that 
both transgenic mice, K5-GR and K5-GR-
TR use the same k5 regulatory sequences, 
along with our data indicating that both 
transgenes are expressed at similar protein 
levels allows us to compare the impact of 
GR vs GR-TR in keratinocytes in vivo (7, 
Fig. 1 and data not shown). 
A major finding of the current 
study is that GR-mediated transrepression is 
sufficient to impair the development of 
eyelid and cornea epithelia (Fig. 2), since 
K5-GR-TR mice showed an ocular 
phenotype indistinguishable from K5-GR 
mice (8). Interestingly, the characterization 
of several knock out mouse models has 
allowed the identification of at least two 
signaling pathways in the control of eyelid 
closure (reviewed in 22). One pathway 
involves the transduction of TGF-β and 
activin signals by the MEKK1/JNK/c-Jun 
pathway and the second pathway involves 
TGF-α/EGFR/ERK signaling. Previous 
reports have shown that both JNK1-/-/JNK2-
/-
 and c-jun conditional knock out in 
epidermis (c-jun-Δep) display an EOB 
phenotype (13-15). In c-jun-Δep mice, the 
ocular phenotype was ultimately due to 
reduced EGFR expression; however, in 
JNK-deficient embryos, decreased EGFR 
signaling despite normal levels of EGFR, 
caused ocular anomalies. Remarkably, we 
did not find changes in JNK/c-Jun activities 
in K5-GR-TR eyelids (Fig. 2C), which 
indicates that JNK-dependent 
phosphorylation of c-Jun is not sufficient to 
mediate normal eyelid closure and that 
alternate pathways regulate the process of 
eyelid fusion. We examined EGFR 
expression and activity in the leading edge 
of 16.5 dpc eyelids in HT, HM and wt
littermates but our results were not 
conclusive since the expression of these 
markers were very weak in both transgenic 
and wt embryos (not shown). Overall, our 
findings suggest that GR elicits the EOB 
phenotype by additional pathways which 
remain to be defined.  
This study also raises another 
interesting issue, namely, that the 
mechanisms by which GR mediates 
epithelial morphogenesis are tissue-
specific. Supporting this hypothesis, the 
transrepression function of GR was 
sufficient to induce dysmorphogenesis in 
some epithelia (eyelid and cornea) while 
both transactivation- and transrepression-
dependent functions were seemingly 
required for abnormal development in other 
tissues (developing epidermis and HF, teeth 
and secretory Meibomian glands) (Figs. 2, 
3 and data not shown; 9). Moreover, the 
mechanisms governing GR action in 
distinct epithelia differ in embryos vs adult 
individuals. The failure of GR to produce 
skin anomalies during embryonic 
development contrasts with the epidermal 
atrophy and reduced HF number observed 
in adult transgenic mice (Figs. 3 and 4). 
Anti-proliferative vs anti-inflammatory 
effects of GR: requirement of 
transrepression and transactivation  
Our results in the two independent K5-GR-
TR lines studied were highly reproducible, 
thus ruling out insertion-dependent effects 
of the transgene. Furthermore, the observed 
phenotypes correlated with transgene 
dosage, as demonstrated by a comparison 
9between lines 298 and 306 as well as the 
severity of defects observed in HM vs. HT 
mice of line 298 (Fig. 4E-H). The use of 
K5-GR-TR and K5-GR mice to analyze the 
proliferative and inflammatory responses to 
PMA in vivo has allowed us to compare the 
requirements of transrepression and 
transactivaction functions in these 
processes (Fig. 5). 
Our data show that the anti-
proliferative actions exerted by GR-TR and 
GR in keratinocytes were very similar in 
acute and chronic PMA processes (Fig. 4). 
We here demonstrate that the anti-
proliferative effects of K5-GR-TR in PMA-
treated keratinocytes rely on the repression 
of both JNK and NF-κB activities and do 
not require GRE-dependent activation 
(Figs. 4, 6 and 7), in agreement with 
previous reports where this mutant was 
tested in several cell lines (11, 23). Our data 
showed that GR-TR inhibited PMA-
induced NF-κB- binding following 1-wk of 
PMA treatment and not at early time-points 
(Fig. 7A). However, given that GR-
mediated inhibition of NF-κB activity does 
not necessarily rely on reduced NF-κB 
binding to DNA, it is plausible that GR-TR 
may exert a dual effect by repressing gene 
transcription without affecting DNA 
binding at early times and reducing DNA 
binding at later stages of PMA treatment. 
Since GR negatively regulated JNK 
activity after PMA treatment and given that 
JNK positively regulates AP-1 function 
through phosphorylation of c-Jun, AP-1 
activity would be expected to be diminished 
in the skin of K5-GR-TR mice. 
Accordingly, we detected reduced 
transcription of the AP-1 target gene MMP-
3 (Fig. 5), which is regulated in an 
antagonistic manner by phorbol esters and 
GCs (17). Additionally, we found that k6β
mRNA, the inducible isoform of k6 which 
also contains AP-1 sites in its promoter, 
was strongly reduced in PMA-treated skin 
of K5-GR-TR mice (Fig. 4D). It has been 
described that GR represses K6 through 
GR/AP-1 negative cross-talk as well as 
through binding of GR monomers to 
nGREs at its promoter (24). In our model, 
both mechanisms could account for the 
observed repression of K6 and support the 
role of the transrepression function of GR 
in the inhibition of keratinocyte 
proliferation. On the other hand, our results 
indicate that GR-TR represses AP-1-
dependent transcription induced by PMA, 
despite detection of increased levels of Jun 
and Fos proteins in untreated skin, (Fig. 
6A). 
The anti-inflammatory effects of 
GR-TR and GR differed, as demonstrated 
primarily by reduction of dermal infiltrates 
(Fig. 4G) and more importantly, by the 
differential repression of several pro-
inflammatory genes (Fig. 5). Although 
previous reports claim that GR protein 
interactions are sufficient to mediate GC 
anti-inflammatory effects (3), we found 
only a weak reduction of inflammatory 
infiltrates in the dermis of transgenic K5-
GR-TR upon exposure to PMA relative to 
the response observed in wt littermates, 
whereas this reduction was statistically 
significant in K5-GR mice (Fig. 4). 
Moreover, the addition of Dex reduced 
dermal cellularity to a similar extent in all 
genotypes, including wt mice, thus 
suggesting that the effect of this ligand was 
mediated by the endogenous GR. In Fig. 5, 
we show that GR-TR and GR differentially 
repressed several pro-inflammatory genes, 
with IL-1β and MMP3 being the most 
affected. The fold repression of IL-1β and 
MMP3 after PMA treatment (4h and 48h) 
was equivalent for K5-GR-TR line 298 and 
K5-GR but less pronounced in the K5-GR-
TR line 306 (Fig. 5), in agreement with 
transgene expression levels (Fig. 1 and data 
not shown). However, the induction of IL-6
and TNF-α genes by PMA was 
significantly reduced in K5-GR but not K5-
GR-TR skin, as compared with wt
littermates. Very recently, it has been 
shown that, in contact allergy, GR requires 
GRE-dependent transcription for the 
suppression of allergic inflammation 
specifically in macrophages (25). This 
report demonstrated that GR dimerization is 
required in macrophages for the repression 
of certain cytokine genes (e.g.IL-1β and 
MCP-1) but not for others such as TNF-α
(26). Our results indicate that 
transactivation also plays a role in the GR-
mediated transrepression of certain pro-
inflammatory genes in vivo. The situation 
could be even more complex, as it has been 
reported that the up-regulation of the MAP 
kinase phosphatase-1 (MKP-1) by GCs 
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contributed to their anti-inflammatory 
effects in a cutaneous air pouch model (26-
28). However, in other models of 
inflammation, both MKP-1-dependent and -
independent components of the anti-
inflammatory action of GCs may coexist in 
a single cell type (28). We examined MKP-
1 at the mRNA and protein level and found 
no differences between K5-GR-TR, K5-GR 
and wt mice, in the absence or presence of 
Dex (not shown). Thus, our results indicate 
that the anti-proliferative action exerted in 
vivo by GR in keratinocytes does not 
involve MKP-1 (data not shown). 
The generation of selective GR-
agonists (SEGRA) has provided valuable 
information regarding the dissociation 
between transrepression and 
transactivation, however, it is still unclear 
which mechanisms are responsible for the 
adverse effects elicited by GCs (1, 4, 10). A 
previous study evaluating the side-effects of 
the SEGRA compound ZK 216348 
demonstrated that after prolonged 
treatment, skin thinning was less-
pronounced as compared to the classical 
GC prednisone, thus suggesting that 
transactivation may be involved in skin 
atrophy (29). In K5-GR-TR adult mice, the 
expression of the transgene inhibited 
growth in epidermal keratinocytes as well 
as HF density, similar to the skin atrophy 
and occasional alopecia observed after 
prolonged treatments with GC analogs in 
human patients (10). However, GR-induced 
skin atrophy does not necessarily use the 
same molecular mechanisms implicated in 
the anti-proliferative actions mediated by 
GR in response to PMA exposure. The 
generation and functional characterization 
of K5-GR-TR mice demonstrates that the 
anti-proliferative effects of GR are 
mediated solely through its transrepression 
function, specifically by impairing 
JNK/AP-1 and NF-κB signaling pathways, 
whereas the GR-mediated anti-
inflammatory actions appear to use both 
transrepression and transactivation 
mechanisms. These findings may have 
implications for understanding the 
therapeutic potential of wt GR, which 
functions as a potent tumor suppressor in 
skin tumorigenesis (30, 31). Given that both 
sustained hyperplasia and persistent 
inflammation are hallmarks of tumor 
formation (32), K5-GR-TR mice represent 
a powerful tool to decipher the contribution 
of inhibiting proliferation and inflammation 
in the prevention and/or treatment of 
epithelial skin tumours. 
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Materials and methods
Generation of transgenic mice 
The cDNA encoding the rat glucocorticoid 
receptor mutant, which contains a double 
mutation (P493R, A494S) rendering a GR 
defective in transactivation but effective in 
transrepression (11), was placed into a 
cassette containing the 5.2 kb bovine 
keratin 5 (bk5) regulatory sequences, the 5´ 
β-globin intron 2 and the 3´ 
polyadenylation sequences (33). The 
transgene construct, denominated K5-GR-
TR, was excised from the plasmid vector 
with NotI, isolated from agarose gels and 
purified by Elutip columns (Schleicher and 
Schuell, Dassel, Germany), adjusted to a 
final concentration of 2  μg/ml and 
microinjected into (C57BL/6J X DBA/2J) 
F2 mouse embryos, as previously described 
(34). Founder mice and progeny were 
identified by PCR analysis of tail genomic 
DNA using specific primers that recognize 
either mouse GR (endogenous) or rat GR 
(transgene).  
Transgenic mice from two 
independent K5-GR-TR HT lines (298 and 
306) were analyzed to rule out insertion-
dependent effects. Results of both lines are 
shown in Figs. 4 and 5. For the other 
experiments, only results from line 298 are 
illustrated. Routinely, the mating schedule 
was programmed by intercrosses of HT 
mice with wt mice, thus obtaining 50% of 
transgenic and 50% of nontransgenic 
progeny, the latter being used as controls. 
In addition, HM mice of line 298 were 
generated although this line was difficult to 
maintain since HM females had difficulties 
in lactating their litters. The total number of 
control and K5-GR-TR transgenic mice 
examined was 270. Of these, 78 were late 
embryos and newborn mice and 192 were 
adult mice. K5-GR heterozygous mice (line 
285) have been previously reported (7). 
Animal handling and Treatments
Mice were housed in microisolated boxes in 
which the air is filtered in both directions, 
allowing maximum isolation. Animal 
experimentation was always conducted 
with accepted standards of humane animal 
care in our registered animal facility (CV-
46007, Centro de Investigación Príncipe 
Felipe CIPF). Experiments were performed 
in accordance with the “Principles of 
Laboratory Animal Care” (NIH Publication 
no. 85-23, revised 1985) and with the 
current Spanish and European normative 
which governs research with animals (Real 
Decreto 1201/2005, B.O.E. #252, 10 of 
October, 2005 and Convenio Europeo 1-2-3 
del 18/3/1986). 
Embryos were obtained by cesarean 
derivation at 18.5 days post-conception 
(d.p.c.; the morning of the day that the 
vaginal plug was seen was considered as 
day 0.5 p.c.). In all experiments performed 
in adult mice, female mice in the resting 
stage of the hair cycle (8-10 weeks of age) 
were used. Dorsal skins were shaved 48 h 
before the treatments. At the indicated 
times, skin was excised and either 
homogenized to obtain RNA and protein, or 
fixed for immunohistochemical analysis. At 
least, 3 or 4 animals per experimental group 
were examined. In the control group, 
animals were treated with vehicle (acetone) 
only. 
Phorbol 12-myristate 13-acetate 
(PMA, Sigma, St. Louis, MO) and 
dexamethasone (Dex, Sigma, St. Louis, 
MO) were applied topically at the indicated 
doses and times. PMA was given at a 
unique dose of 8 μg/mouse in the acute 
treatments (2-48h) and repeatedly applied 
every other day at 2 μg/mouse in the 
chronic treatments for 1- to 3-wks. Dex 
(8 μg/mouse in 200 μl) was topically 
applied 24h before PMA treatment.  
Antibodies 
The antibodies used included rabbit 
polyclonal antibodies to GR (sc-1004), 
ERK (sc-154), JNK (sc-474), P-c-jun (sc-
822), p65 (sc-372), IκBα (sc-371), c-Fos 
(sc-52) from Santa Cruz Biotechnology, 
Inc., (Santa Cruz, CA). Antibodies against 
c-jun (#9165), P-ERK (Thr202/Tyr204) 
(#4376) P-JNK (Thr183/Tyr185) (#9251) 
were purchased from Cell Signaling (Cell 
Signaling Technology Inc., Beverley, MA). 
An antibody against actin (A-2066, Sigma 
Chemical Co., St. Louis, MO) was used for 
loading control. Secondary peroxidase-
conjugated anti-rabbit antibody was from 
Amersham (Aylesbury, UK) and secondary 
peroxidase-conjugated anti-mouse antibody 
and biotin-conjugated anti-rabbit or anti-
mouse antibodies from Jackson 
ImmunoResearch (Jackson 
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ImmunoResearch Laboratories, Inc. West 
Grove, PA). 
Antibodies against keratin K5 
(PRB-160P), K6 (PRB-169P) and K10 
(PRB-159P) were from Covance (Babco, 
Berkeley, CA). 
Transfection studies 
PB cell line (mouse adult non-transformed 
keratinocytes) was grown in Dulbecco's 
modified Eagle's medium (BioWhitakker, 
Inc., Walkersville, MD) supplemented with 
10% fetal calf serum (BioWhitakker, Inc.). 
Transient transfection assays were done by 
the calcium phosphate method using either 
MMTV-CAT or 8x-κB-CAT reporter 
plasmids along with expression vectors 
encoding for empty vector (pcDNA3), K5-
GR or K5-GR-TR (5 μg/each). To 
determine MMTV-CAT activity, PB cells 
were incubated with charcoal-stripped 
serum overnight to deplete endogenous 
GCs and then treated with either vehicle or 
Dex (1 μM) for 6 h. In transfections 
experiments using 8x-κB-CAT reporter, PB 
cells were treated with either vehicle or 
TNF-α (10 ng/ml) for 4 h. CAT activity 
was assayed by the CAT ELISA kit (Roche 
Molecular Biochemicals, Indianapolis, IN) 
according to the manufacturer's 
recommendations. Three independent 
experiments were performed in triplicate 
and mean value ± SD estimated. Statistical 
significance was analyzed by Student’s t 
test.
Histological and Immunohistochemical 
analysis 
Whole embryos, newborn mice and skin 
samples were paraformaldehyde- or 
ethanol-fixed and embedded in paraffin. 
Consecutive 4 μm-thick sections were 
obtained and routinely stained with 
hematoxylin/eosin. Briefly, for 
immunostaining, paraffin sections were 
dewaxed, microwaved in 10 mM citrate 
solution and blocked with 1% bovine serum 
albumin (BSA). Then, slides were 
incubated with the primary antibody for at 
least one hour, washed three times with 
PBS, and then incubated with conjugated 
secondary antibodies for 1h. Finally, the 
reaction was visualized with the Avidin-
Biotin-Complex (ABC) kit from DAKO 
(Vectastain Elite, Vector Laboratories, Inc, 
Burlingame, CA) using diamino-benzidine 
as chromogenic substrate for peroxidase. 
Slides were mounted and analyzed by light 
microscopy (Leica DM RXA2), and 
microphotographs were taken at the 
indicated magnification.  
BrdU labeling 
Epithelial cell proliferation was measured 
by i.p. injection of BrdU (130  μg/g of body 
weight, Roche, Germany) 1 h before 
sacrifice. BrdU incorporation was detected 
by immunohistochemistry of paraffin-
embedded sections using a mouse anti-
BrdU monoclonal antibody (Roche, 
#1170376). The number of BrdU-positive 
cells and the number of total cells was 
determined in at least 6 mm of 
interfollicular epithelium in each sample. 
Data reflect the average from 5 mice of 
each genotype (WT, K5-GR-TR line 298 
HT, K5-GR-TR line 298 HM, K5-GR-TR 
line 306 and K5-GR line 285). Error bars 
indicate SD. Statistical significance was 
determined by Student’s t test comparing 
the PMA response (acute and chronic) of 
each genotype relative to PMA-treated wt
mice. Statistical differences of PMA+Dex 
vs PMA-treated wt are also shown. 
Morphometric analysis 
Quantitation of the epidermal width, dermal 
cellularity and average number of HFs was 
performed in dorsal skin sections stained 
with hematoxilin/eosin. At least 10 
individual fields of 1mm per slide were 
counted using the software MetaMorph 
(Premier Offline 7.0, Molecular Devices).
Experiments were performed at least in five 
individuals of each genotype and 
differences were assessed by using the t 
test, with statistical significance when p < 
0.05.
RNA preparation and Semiquantitative RT-
PCR 
Total RNA was isolated from back skin of 
newborn and adult transgenic and control 
mice by using Trizol reagent (Invitrogen, 
Molecular Probes, Eugene, Oregon), 
following manufacturer´s 
recommendations. Reverse transcription 
was performed by using 1 μg of RNA and 
oligo-dT (Fermentas Inc., Burlington, 
Canada) followed by PCR using specific 
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oligonucleotides for k6β (forward: 5´-
CACCATCAAATACACCACCAGCG-3´; 
reverse: 5´-
AAGCAGCCAAAAAGAGAAGCGAG-
3´); TNF-α (forward: 5´-ATG AGC ACA 
GAA AGC ATG ATC-3´; reverse: 5´-TAC 
AGG CTT GTC ACT CGA ATT-3´), IL-6
(forward: 5´-GAC AAA GCC AGA GTC 
CTT CAG AGA G-3´; reverse: 5´-CTA 
GGT TTG CCG AGT AGA TCT C-3´), IL-
1β (forward: 5´-ATG GCA ACT GTT CCT 
GAA CTC ACC T-3´; reverse: 5´-CAG 
GAC AGG TAT AGA TTC TTT CCT TT-
3´), cyclin D1 (forward: 5´-CAT CAA GTG 
TGACCC GGA CTG-3´; reverse: 5´-CCT 
CCT CCT CAG TGG CCT TG-3´), MMP-3
(forward: 5´-TGT ACC CAG TCT ACA 
AGT CCT CCA C-3´; reverse: 5´-CTG 
CGA AGA TCC ACT GAA GAA GTA G-
3´), ikba (forward: 5´-CGC CCA AGC 
ACC CGG ATA CAG C-3´; reverse: 5´-
TGG GGT CAG TCA CTC GAA GCA 
CAA-3´) and β-actin (forward: 5´-CCA 
CCA GAC AAC ACT GTG TTG GCA T-
3´; reverse: 5´- AGA GGT ATC CTG ACC 
CTG AAG TAC C-3´). To achieve 
semiquantitative amplification, 25 cycles 
were used; bands corresponding to specific 
PCR products were scanned by using Image 
Quant (Amersham), quantitated with 
Quantity One Software (BioRad) and 
values were estimated relative to β-actin 
levels. Experiments were performed at least 
in three individuals of each genotype and 
differences were assessed by using the t 
test, with statistical significance when p < 
0.05.
Immunoblotting 
Whole cell extracts and cytoplasmic and 
nuclear extracts (20 μg) were prepared as 
previously described (30), boiled in 
Laemmli buffer and separated on 10% 
sodium dodecyl sulfate-polyacrylamide gels 
(SDS-PAGE), then transferred to 
nitrocellulose filters (Hybond ECL, 
Amersham, Aylesbury, UK). Filters were 
blocked with 5% nonfat dry milk in PBS-
0.1% Tween 20 at 4º C overnight, washed 
three times in PBS-0.1% Tween 20 and 
incubated with the indicated antibodies. 
After washing, membranes were incubated 
with a peroxidase-conjugated secondary 
antibody (Amersham), washed again, and 
analyzed using the enhanced 
chemiluminiscence method (ECL, 
Amersham), according to manufacturer´s 
recommendations. The membranes were 
stained with Ponceau S to verify equal 
protein loading and transfer.  
Specific bands were scanned by 
using Image Quant (Amersham), 
quantitated with Quantity One Software 
(BioRad) and graph plotted. Values for 
control samples (basal protein levels in wt
skin) were arbitrarily set as 1 and other 
values were expressed as relative to wt. 
Experiments were performed at least in 
three individuals of each genotype and 
differences were assessed by using the t 
test, with statistical significance when p < 
0.05.
EMSA 
Electrophoretic mobility shift assays 
(EMSA) were performed by incubating 
total cell extracts from mouse skin with a 
labeled oligonucleotide corresponding to a 
palindromic κB site previously described 
(30). Complexes were separated on 5.5% 
native polyacrylamide gels in 0.25x Tris-
borate-EDTA buffer, dried and exposed to 
Hyperfilm-MP (Amersham) at -70 ºC. 
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Figure Legends 
Figure 1. Generation of K5-GR-TR transgenic mice expressing a mutant GR in keratinocytes 
that is defective in transactivation but effective in transrepression.
A) Scheme of the construct K5-GR-TR. The cDNA of GR containing a double mutation 
(P493R, A494S) was placed under control of bovine keratin 5 (bk5) regulatory sequences. B)
PB keratinocytes were transiently transfected with either MMTV-CAT or 8x-κB-CAT reporter 
plasmids along with expression vectors encoding for empty vector (pcDNA3), K5-GR or K5-
GR-TR. After depletion of endogenous GCs, cells were treated with either vehicle or 1 μM Dex 
for 6 h to determine MMTV-CAT activity. In transfections using 8x-κB-CAT reporter, vehicle 
or TNF-α (10 ng/ml) were added for 4 h before measuring CAT activity (a.u, arbitrary units). 
Data presented are average of three independent experiments, each performed in triplicate. Error 
bars indicate SD. Asterisks denote statistically significant differences relative to pCDNA3-
transfected cells, as analyzed by Student’s t test (*, p < 0.0005). Expression levels for the wt and 
mutant GR upon transfection were checked by immunoblotting (lower panel). C) RT-PCR 
analysis showing the endogenous (mGR) and transgene (rGR) transcript levels in the skin of wt
and K5-GR-TR adult littermates. D) Immunoblotting using whole cell extracts from tail and 
dorsal skin of three transgenic founders (298, 306 and 599) to check the relative expression 
levels of GR. E) Immunolocalization of GR in dorsal skin paraffin sections from newborn wt
and transgenic mice. Arrows indicate the nuclear localization of GR in the interfollicular basal 
epithelium and the outer root sheath (ORS) of HFs in transgenic skin. Bar= 25 μm
Figure 2. Lack of Eyelid Closure in K5-GR-TR embryos 
A) Eyelid fusion failed in 18.5 dpc K5-GR-TR homozygous embryos as compared to wt mice. 
B) Immunostaining using K5 in wt and K5-GR-TR embryos demonstrating the epithelia to 
which transgene expression is targeted. Cornea (a, d), conjunctiva (b, e), eyelid epithelium (c, f); 
fused eyelids in wt embryos are pointed by an arrowhead. a-f are also shown at higher 
magnification in the lower panel. Note that K5 staining was lacking in the cornea epithelium 
whereas it appeared as more restricted in K5-GR-TR eye embryos. Additional ocular defects, 
including microphtalmia, dysplastic retinal tissue and attachment of eyelid epithelium to the 
posterior side of the cornea were observed in K5-GR-TR transgenic embryos (arrow). C)
Immunostaining using P-c-Jun and P-JNK antibodies revealed no differences in the expression 
of these phosphorylated proteins in the eyelid epithelium of K5-GR-TR versus wt embryos. 
Arrows indicate nuclear localization of P-c-Jun and P-JNK. D) Adult transgenic mice exhibited 
corneal opacity. E) The secretory Meibomian glands of the eyelids were unaffected in the 
transgenics (arrowheads). Bar= 50 μm 
Figure 3. Normal embryo skin development and adult skin alterations in K5-GR-TR mice 
A) Normal development of the epidermis and HFs in 18.5 dpc K5-GR-TR homozygous (HM) 
mice. Immunostaining with K5 and K10 showed no alterations in transgenic embryo skin as 
compared to controls. B) Adult HM transgenic mice developed patchy alopecia along the whole 
coat (left) and throughout the face, with scarce and underdeveloped vibrissae (right). C)
Immunostaining using an anti-K5 antibody showed a discontinous pattern in the epidermis of 
adult HM mice (arrows). Bar= 50 μm 
Figure 4. GR-TR inhibits PMA-induced proliferation upon acute and chronic treatment.
A, B) Responses of adult K5-GR-TR and K5-GR to acute PMA treatment. Age-matched adult 
wt, K5-GR-TR heterozygous (HT) mice of lines 298 and 306, and K5-GR mice (line 285) were 
used for these experiments. The proliferation rate of interfollicular epidermal keratinocytes was 
evaluated in dorsal skin paraffin sections from the indicated genotypes, as indicated in Materials 
and Methods. Arrows indicate BrdU-positive interfollicular keratinocytes. Results of the 
quantification were graphed as the percentage of positive BrdU keratinocytes vs total nuclei. 
Mean values ± SD are shown (n=5). Asterisks denote statistical significance differences relative 
to PMA-treated wt mice, as determined by Student’s t test (*, p<0.05; **, p<0.005). C)
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Responses of adult K5-GR-TR and K5-GR mice to chronic PMA (1-wk). Age-matched adult 
wt, K5-GR-TR HT and HM mice of line 298 and K5-GR mice (line 285) were used for these 
experiments. Hematoxylin/eosin staining shows dramatic epidermal hyperplasia in wt mice that 
was greatly reduced in HT and HM skin as well as in K5-GR mice. K6 staining was evaluated 
as a marker of hyperproliferative skin. Bar= 50 μm except for K6 immunostaining, where Bar= 
25 μm. D) Determination of the mRNA levels of k6β by RT-PCR in wt and K5-GR-TR HM 
skin that was treated with either vehicle (-) or PMA for 1-wk. Experiments were performed at 
least in three individuals of each genotype. Quantitation of RT-PCR is shown at right. Mean 
values ± SD are shown (n=3) and statistically significant differences (p < 0.05) are indicated by 
asterisks. E-H) Responses of adult K5-GR-TR and K5-GR to PMA (1-wk) and PMA+Dex (1-
wk) (P+D). Age-matched adult wt, K5-GR-TR HT and HM mice of line 298, K5-GR-TR mice 
of line 306 and K5-GR mice (line 285) were used for these experiments. Morphometric analyses 
were performed to determine epidermal width (E), dermal cellularity (G) and number of 
HFs/mm (H) in mouse skin of the indicated genotypes. Percentage of BrdU incorporation was 
also examined in the same skin samples (F). Note that the inhibition of epidermal keratinocyte 
growth correlated with transgene dosage (compare HT vs HM) and was consistently observed in 
the two independent transgenic lines (298 and 306). Morphometric and BrdU measurements 
were performed at least in five individuals of each genotype. Mean values ± SD are shown. 
Asterisks indicate statistical significance of the response of each genotype as compared to 
PMA-treated wt mice, as determined by Student’s t test (*, p<0.05; **, p<0.005; ***, 
p<0.0005).  
Figure 5. GR-TR differentially regulates pro-inflammatory cytokines in vivo 
Determination of the mRNA levels of IL-6, TNF-α, cycD1, IL-1β and MMP-3 in mouse skin of 
the indicated genotypes. Mice were treated with either vehicle, PMA for 4h or 48h, or pre-
treated with Dex for 24h before PMA application. For quantitation of RT-PCR, experiments 
were performed at least in three individuals of each genotype. Mean values ± SD are shown. 
Values representing gene expression levels of untreated mice from each genotype were set to 1; 
fold-induction is thus represented relative to this basal level. Asterisks denote statistically 
significant differences relative to wt mice with the same treatment, as determined by Student’s t 
test (*, p<0.05; **, p<0.005). 
Figure 6. GR-TR abrogates the PMA-induced activation of JNK at early time points 
A) Immunoblotting using whole cell extracts from adult K5-GR-TR and wt dorsal skin that 
were either untreated or treated with PMA at the indicated times to check the expression of 
ERK, P-ERK, JNK, P-JNK, c-Jun and c-Fos. B) Quantitation of the relative levels of P-
ERK/ERK and P-JNK/JNK was determined in at least three individuals of each genotype. 
Figure 7. GR-TR reduces NF-κB activation at later stages
A) EMSA showing NF-κB-binding activity of total skin extracts from wt and transgenic mice 
that were either untreated or PMA-treated for the indicated times. The composition of the NF-
κB complexes (p50/p65 and p50/p50 dimers) was determined by supershift assays (right panel). 
PI, preimmune serum. Free probe is indicated at the gel bottom. B) Cytoplasmic and nuclear 
extracts were prepared from adult K5-GR-TR and wt skin to examine the expression of p65 
and ΙκBα by using specific antibodies. C) RT-PCR analysis showing ikba transcript levels in 
skin from adult wt, K5-GR and K5-GR-TR mice. 
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